| Literature DB >> 32784070 |
Kotaro Miyao1, Seitaro Terakura2, Fumihiko Kimura3, Takaaki Konuma4, Koichi Miyamura5, Masamitsu Yanada6, Shinichi Kako7, Satoko Morhishima8, Naoyuki Uchida9, Takashi Toya10, Yukiyasu Ozawa5, Takahiro Fukuda11, Masatsugu Tanaka12, Masashi Sawa13, Satoru Takada14, Shuro Yoshida15, Takafumi Kimura16, Tatsuo Ichinohe17, Yoshiko Atsuta18, Junya Kanda19.
Abstract
The outcomes of 7/8 allele-matched unrelated bone marrow transplantation (7/8 UBMT) and umbilical cord blood transplantation (UCBT) have been improving. We retrospectively analyzed adults with acute leukemia who underwent their first 7/8 UBMT or UCBT in Japan. Between January 2008 and December 2017, a total of 4150 patients were recorded, including 488 who underwent 7/8 UBMT and 3662 who underwent UCBT. Only 32 patients with 7/8 UBMT had graft-versus-host-disease (GVHD) high-risk HLA mismatched pairs. Overall survival at 3 years was 54% for 7/8 the UBMT group and 46% for the UCBT group, a nonsignificant difference in multivariate analysis (hazard ratio [HR], 1.01; 95% confidence interval [CI], .88 to 1.17; P = .89). The 7/8 UBMT and UCBT groups showed a similar nonrelapse mortality rate (HR, 1.16; 95% CI, .96 to 1.45; P = .16) and relapse rate (HR, .85; 95% CI, .71 to 1.02; P = .08). However, the UCBT group had a lower risk of grade II-IV acute GVHD (HR, .76; 95% CI, .65 to .88; P < .001) and chronic GVHD (HR, .77; 95% CI, .66- .91; P = .002) compared with the 7/8 UBMT group. In stratified analyses combining disease risk with conditioning intensity, 7/8 UBMT showed superior overall survival to UCBT in standard risk and myeloablative conditioning (HR, .72; 95% CI, .56 to .93; P = .014). Both 7/8 UBMT and UCBT are appropriate alternative donor procedures. The stem cell source can be selected on the basis of disease risk, patient tolerability, or concerns regarding GVHD.Entities:
Keywords: Acute leukemia; Alternative donor; Umbilical cord blood transplantation; Unrelated bone marrow transplantation
Mesh:
Year: 2020 PMID: 32784070 DOI: 10.1016/j.bbmt.2020.08.001
Source DB: PubMed Journal: Biol Blood Marrow Transplant ISSN: 1083-8791 Impact factor: 5.742